U.S. Markets close in 47 mins

FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This follows review of the Phase 2 clinical data evaluating pamrevlumab in a placebo-controlled trial and represents recognition by the FDA that pamrevlumab has the potential to address an unmet medical need for this disease.

“This Fast Track designation reflects recognition of the great need for a new therapeutic to help patients diagnosed with IPF to reduce the burden and progression of this debilitating disease and another positive step in developing pamrevlumab for the treatment of IPF,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety. “We look forward to advancing pamrevlumab into Phase 3 studies early next year.”

About Fast Track Designation
Fast Track designation is intended to facilitate the development and review of drugs used to treat serious conditions and to fill an unmet medical need. Fast Track designation enables the company to have more frequent interactions with the FDA throughout the drug development process, so that an approved product can reach the market expeditiously.

About Idiopathic Pulmonary Fibrosis 
IPF is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As tissue scarring progresses, transfer of oxygen into the bloodstream is increasingly impaired, leading to irreversible loss of lung function, as well as high morbidity and mortality rates. Average life expectancy is estimated to be three to five years from diagnosis with approximately two-thirds of patients dying within five years. Survival rates are comparable to those of some of the deadliest cancers.

Patients with IPF experience debilitating symptoms, including shortness of breath and difficulty performing routine functions, such as walking and talking. Other symptoms include chronic dry, hacking cough, fatigue, weakness, discomfort in the chest, loss of appetite, and weight loss. Over the last decade, refinements in diagnosis criteria and enhancements in high-resolution computed tomography (HRCT) imaging technology have enabled more reliable diagnosis of IPF without the need for a lung biopsy.

IPF is designated as an orphan disease by the U.S. Food and Drug Administration, with U.S. prevalence and incidence estimated to be 135,000 cases (defined by ICD-9 code) and 21,000 new cases per year, respectively, based on Raghu et al. (Am J Respir Crit Care Med, 2006) and on data from the United Nations Population Division. We believe the number of patients will continue to grow due to heightened awareness and improved methods for detection and diagnosis.

About Pamrevlumab
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer and has been granted Orphan Drug Designation (ODD) in each of these indications, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). Pamrevlumab has received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with locally advanced unresectable pancreatic cancer. Across all trials, pamrevlumab has consistently demonstrated a good safety and tolerability profile to date. For information about pamrevlumab studies currently recruiting patients, please visit www.clinicaltrials.gov.

About FibroGen
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) currently under review in China by the State Drug Administration (SDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS). Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.

Forward-Looking Statements
This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the company’s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, and our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2018 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Investor and Media Contact
Karen L. Bergman
Vice President, Investor Relations and
Corporate Communications
FibroGen, Inc.
kbergman@fibrogen.com
(415) 978-1433

  • Business
    Benzinga

    Morgan Stanley Says Intel 'Oversold' Its Technology, Raises AMD Price Target 150%

    Morgan Stanley's Joseph Moore maintained an Underweight rating on AMD with a price target lifted from $11 to $28. Intel argued over the past few years that its process leadership would translate into a sustainable performance advantage across multiple markets, Moore said in a Tuesday note. Intel's ongoing delays in its 10 nm processors are now looking more disruptive for the company than previously assumed, as it is impacting existing roadmaps, Moore said.

  • Business
    TheStreet.com

    Tilray Shares Are Going Absolutely Haywire -- Here's Why

    It may end badly, but for nimble traders in Tilray the good times are likely to continue flowing as the hype on the company's prospects reach fever pitch levels. Tilray shares spiked another 50% on Wednesday's session following a bullish interview by CEO Brendan Kennedy on 'Mad Money', hosted by TheStreet's founder Jim Cramer. Clearly, investors have bought into Tilray's pitch hook, line and sinker.

  • The $100,000 stocks that Kanye West bought Kim Kardashian for Christmas are up by 40% (DE000A1EWW, US02313510)
    News
    Business Insider

    The $100,000 stocks that Kanye West bought Kim Kardashian for Christmas are up by 40% (DE000A1EWW, US02313510)

    Kim Kardashian West might have a future on Wall Street. The reality TV star was gifted shares in five major companies for Christmas last year by her husband Kanye West. The stocks have since soared 40% on average, according to data from Markets Insider.

  • 2 Utility Stocks to Buy and 1 to Avoid
    Business
    Motley Fool

    2 Utility Stocks to Buy and 1 to Avoid

    Investing in utilities is usually a pretty boring affair, with the main attraction normally being a reliable quarterly dividend payment. Recent events at SCANA Corporation (NYSE: SCG), however, have been anything but boring. Dominion Energy could be the company's savior, but not if the government gets in the way.

  • Can CenturyLink's Dividend Even Survive?
    Business
    Motley Fool

    Can CenturyLink's Dividend Even Survive?

    It's easy to see why so many investors are bearish on Telecom giant CenturyLink Inc. (NYSE: CTL). Its legacy business is expected to continue shrinking, and it has paid out more in dividends than it has earned in profits for years. Oh, and there's even

  • JPMorgan Enhances Shareholder Wealth with 43% Dividend Hike
    Business
    Market Realist

    JPMorgan Enhances Shareholder Wealth with 43% Dividend Hike

    As part of its capital return plan, JPMorgan Chase (JPM), the largest US bank, has declared a massive 43% rise in its quarterly cash dividend. The bank will pay the dividend on October 31 to shareholders of record as of October 5. Based on yesterday’s closing price of $114.30 per share, the dividend yield is 2.8%, which is the second-highest among the top five US banks based on market capitalization.

  • United updates boarding process, Alibaba expands cloud partnership, Verizon denies accusations
    Business
    Yahoo Finance Video

    United updates boarding process, Alibaba expands cloud partnership, Verizon denies accusations

    United Airlines, Alibaba, Verizon, Amazon and Microsoft are the companies to watch.

  • China says won't weaken currency to boost exports, as U.S. tariffs mount
    Business
    Reuters

    China says won't weaken currency to boost exports, as U.S. tariffs mount

    China will not stoop to competitive devaluation of its currency, Premier Li Keqiang stressed, hours after China hit back, with a softer punch than the one landed by the United States, in an escalating tariff war between the world's largest economies. "One-way depreciation of the yuan brings more harm than benefits for China," he said. China will not do that to chase "thin profits" and "a few small bucks".

  • Analysts Are Bullish on Microsoft Stock
    Business
    Market Realist

    Analysts Are Bullish on Microsoft Stock

    As of September 17, the analysts from different brokerage firms who track Microsoft (MSFT) stock provided their ratings. In the above graph, you can see analysts’ ratings. Microsoft’s commercial cloud revenues maintained a trailing 12-month run rate of $5.8 billion each quarter.

  • Micron Shares Increase prior to Its Quarterly Results
    Business
    Market Realist

    Micron Shares Increase prior to Its Quarterly Results

    These Tech Stocks Rallied on September 18 (Continued from Prior Part) Stock rose 4% yesterday Shares of semiconductor (SMH) company Micron Technology (MU) rose 4% on September 18. The stock is currently trading at $45.33, 33% above its 52-week low of

  • Report: Boeing planning another rate hike on the 737
    Business
    American City Business Journals

    Report: Boeing planning another rate hike on the 737

    Unfazed by supplier bottlenecks that crimped production earlier this year, the Boeing Co. is reportedly already planning to take the rate on the 737 narrow-body to 63 aircraft per month in the future in a development that would drive even more work for

  • SLB, HAL, BHGE, and FTI: Four Oilfield Services Giants
    Business
    Market Realist

    SLB, HAL, BHGE, and FTI: Four Oilfield Services Giants

    SLB, HAL, BHGE, and FTI: Comparing Four Oilfield Services Giants (Continued from Prior Part) Upside potential Based on median target prices from analysts surveyed by Reuters, Schlumberger (SLB), Halliburton (HAL), Baker Hughes (BHGE), and TechnipFMC

  • Did The Home Depot Inc (NYSE:HD) Insiders Sell Their Own Shares?
    Business
    Simply Wall St.

    Did The Home Depot Inc (NYSE:HD) Insiders Sell Their Own Shares?

    The Home Depot, Inc. operates as a home improvement retailer. Home Depot is one of United States’s large-cap stocks that saw some insider selling over the past three months, with insiders divesting from 5.33k shares during this period. The MIT Press (1998) published an article showing that stocks following insider selling underperformed the market by 2.7%.

  • Lockheed Martin makes offers to 800 people at latest Fort Worth hiring event
    Business
    American City Business Journals

    Lockheed Martin makes offers to 800 people at latest Fort Worth hiring event

    Lockheed Martin offered letters of intent to 800 people on Monday to work at its Fort Worth factory, according to a company spokesperson. For almost two years, Lockheed Martin Corp. (NYSE: LMT) has been hosting job fairs to add to its workforce at the Fort Worth facility where the F-35 is manufactured. Since Lockheed Martin is a defense contractor that does a significant amount of work for the U.S. military, the potential employees must pass background checks before they can go to work.

  • AT&T’s Leverage Is a Key Concern
    Business
    Market Realist

    AT&T’s Leverage Is a Key Concern

    AT&T’s Highlights at the Goldman Sachs Communacopia Conference (Continued from Prior Part) High leverage AT&T (T) has high leverage compared to most of its competitors. Its net-debt-to-EBITDA ratio is 2.92x, compared to the industry average of 2.36x.

  • MARKETS: Chinese stocks look like they're bottoming, and a US dollar selloff would help
    Business
    Yahoo Finance Video

    MARKETS: Chinese stocks look like they're bottoming, and a US dollar selloff would help

    Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Seana Smith and Dion Rabouin to discuss the latest moves.

  • Teva finds big tenant to take over lease at its OP headquarters
    Business
    American City Business Journals

    Teva finds big tenant to take over lease at its OP headquarters

    Teva Neuroscience Inc. found a new tenant for its $46 million headquarters in Overland Park. The pharmaceutical giant, which is consolidating its U.S. workforce in a planned New Jersey headquarters, will sublease the 156,000-square-foot building at 11100 Nall Ave. to its neighbor, Netsmart Technologies Inc. On Monday, the Overland Park Finance, Administration and Economic Development Committee approved Netsmart as a tenant.

  • North Korea Agrees to Permanently Dismantle Nuclear Complex If U.S. Takes Corresponding Steps
    World
    Time

    North Korea Agrees to Permanently Dismantle Nuclear Complex If U.S. Takes Corresponding Steps

    The Korean leaders also said the North would dismantle a missile engine test site and launch pad in the presence of outside inspectors, and would seek to host the 2032 Summer Olympics together. Moon also said Kim would try to visit Seoul sometime this year. Washington wants North Korea to outline the entirety of its nuclear program, and its response to Wednesday’s joint statement from the Koreas remains to be seen.

  • iOS 12 review: Apple's new iPhone software will make you use your phone better – and less
    Technology
    The Independent

    iOS 12 review: Apple's new iPhone software will make you use your phone better – and less

    Apple's new iPhone software, iOS 12, arrives today. It's an update fixed with little tweaks, minor improvements, subtle changes. But more importantly it's probably the first time that Apple has released an update that it hopes will stop you using your

  • Why SunPower Corporation Stock Soared 15%
    Business
    Motley Fool

    Why SunPower Corporation Stock Soared 15%

    Worries that Trump Administration's tariffs on solar panels manufactured abroad would hurt American solar companies have weighed on SunPower (NASDAQ: SPWR) stock this year. From a high near $10, SunPower had fallen by as much as one-third through the close of trading yesterday. Today, SunPower stock is soaring -- up 15% as of 1:20 p.m. EDT on Tuesday after a company statement confirming that SunPower has won exemption from the tariffs on its solar panels.

  • Where Will Ferrellgas Partners, L.P. Be in 5 Years?
    Business
    Motley Fool

    Where Will Ferrellgas Partners, L.P. Be in 5 Years?

    Here's what to expect from Ferrellgas Partners over the next five years. Ferrellgas Partners' core business is distributing propane. In early 2014 the partnership decided to try and diversify into the midstream oil and natural gas space, using acquisitions to create a midstream division.

  • This High-Yield Stock Is Working Hard to Cash In on the Fast-Growing Permian Basin
    Business
    Motley Fool

    This High-Yield Stock Is Working Hard to Cash In on the Fast-Growing Permian Basin

    Oil and gas production in the Permian Basin is up more than 50% since December 2016. Among them is that there isn't enough pipeline capacity to move all that oil and gas out of the region. Because of that, pipeline companies are building new infrastructure as fast as they can.

  • Business
    Benzinga

    Needham: Google Private Cloud Reports Create Nutanix Buying Opportunity

    Nutanix Inc (NASDAQ: NTNX) stock jumped Tuesday after selling off by 12 percent Monday following media reports of a major new competitor in the private cloud market. What Happened The Information reported that Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ:

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT

    Q2 2018 MannKind Corp Earnings Call VALENCIA Sep 19, 2018 (Thomson StreetEvents) -- Edited Transcript of MannKind Corp earnings conference call or presentation Thursday, August 2, 2018 at 9:00:00pm GMT TEXT version of Transcript ===================

  • Business
    Benzinga

    Piper Jaffray Pro: History Shows AMD Stock Could Fall Nearly 100%

    If history repeats itself, Advanced Micro Devices, Inc. (NASDAQ: AMD) investors should brace for a 96-percent crash in the stock, according to Craig Johnson. What Happened AMD is among the hottest performers in 2018, with shares up around 225 percent